Biomarqueurs sanguins et urinaires chez les patients atteints d'un syndrome d'apnées obstructives du sommeil (SAOS)Â : comment juger de l'efficacité de la pression positive continue (PPC)Â ?

Obstructive sleep apnea (OSA) patients have perturbations in some plasma and urinary cardiometabolic biomarker levels including catecholamines, inflammatory markers, lipid level elevations or glucose metabolism marker modifications. Many open studies show a beneficial effect of continuous positive airway pressure (CPAP) on these cardiometabolic biomarkers. However, this effect does not seem to be clearly established based on data from randomized and controlled (CPAP versus sham CPAP) trials. A systematic review of these data is thus necessary; in order to detect biomarkers seemingly CPAP sensitive for which regular monitoring may be informative in CPAP treated patients in addition to guidelines corresponding to the patient's profile.